Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug

Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug

Summary: The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible. Here, we identify sphingomyelin phosphodiesterase 1 (SMPD1), an enzyme that regulates the con...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Junfeng Bi, Atif Khan, Jun Tang, Aaron M. Armando, Sihan Wu, Wei Zhang, Ryan C. Gimple, Alex Reed, Hui Jing, Tomoyuki Koga, Ivy Tsz-Lo Wong, Yuchao Gu, Shunichiro Miki, Huijun Yang, Briana Prager, Ellis J. Curtis, Derek A. Wainwright, Frank B. Furnari, Jeremy N. Rich, Timothy F. Cloughesy, Harley I. Kornblum, Oswald Quehenberger, Andrey Rzhetsky, Benjamin F. Cravatt, Paul S. Mischel
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
glioblastoma
sphingolipid metabolism
SMPD1
fluoxetine
Membrane lipids
EGFR signaling
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/8516b7196aa84c49af33aefb9f94a103
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/8516b7196aa84c49af33aefb9f94a103

Ejemplares similares